Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07289399

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both problems

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Psoriasis Adnexal Diseases Cysts Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Neoplasms Ovarian Cysts Ovarian Diseases Polycystic Ovary Syndrome Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Urogenital Diseases

Age range

35 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Forty Women with psoriasis with PCOS will be enrolled to be catogrized to Group I or group II. Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week. Also Group I will follow low calorie diet and daily metformin for 12 weeks. Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • obese (class I) women
  • chronic plaque psoriasis
  • polyscytic ovarian syndrome

Exclusion criteria

  • cardiac dysfucntions
  • liver diseases
  • repsiratory disease
  • vascular diseases

Treatment and study plan

exercise and diet restriction

Behavioral

Group I will enroll twenty females with PCOS and Psoriasis who will apply forty minutes walking on treadmill three times per week for 12 weeks. Also Group I will follow low calorie diet and daily metformin for 12 weeks.

diet restriction

Behavioral

Group II will will enroll twenty females with PCOS and Psoriasis who will follow low calorie diet and daily metformin for 12 weeks

Primary outcomes

  1. Psoariasis area and severity index

    Time frame: it will be measured after 12 weeks

    is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area

Secondary outcomes

  1. body mass index

    Time frame: It will be measured after 12 weeks

    it will be assessed after emptying bladder and bowel

  2. waist circumference

    Time frame: It will be measured after 12 weeks

    it will be measured at level of ambilicus

  3. waist hip ratio

    Time frame: It will be measured after 12 weeks

    it will be assessed after dividing waist circumference on hip circumference

  4. testesterone

    Time frame: it will be measured after 12 weeks

    it will be assessed in serum

  5. ratio of luteinizing hormone and follicle-stimulating hormone

    Time frame: It will be measured after 12 weeks

    it is anindicator on function of sex hormones

  6. Dehydroepiandrosterone

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  7. Dermatology life Quality Index

    Time frame: It will be measured after 12 weeks

    it assess impact of skin disease on quality of life

  8. insuiln

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  9. fasting blood glucose

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  10. HOMA-IR

    Time frame: It will be measured after 12 weeks

    Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is classically considered to be a good insulin resistance (IR) index

  11. triglycerides

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  12. total cholesterol

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  13. high density lipoprotein

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  14. low density lipoprotein

    Time frame: It will be measured after 12 weeks

    it will be assessed in plasma

  15. systolic blood pressure

    Time frame: It will be measured after 12 weeks

    it will be assessed via manual sphygmmanometer

  16. diatolic blood pressure

    Time frame: It will be measured after 12 weeks

    it will be assessed via manual sphygmmanometer

Study contacts

Contact information is provided by the study sponsor or research team.

Ali MA Ismail, lecturer

CONTACT

[email protected]

01005154209

Ali mohamed, lecturer

CONTACT

[email protected]

01031321109

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 17, 2025
Registry last updated
Dec 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.